Clinical Trials Browser

Muscle Invasive Bladder Urothelial Carcinoma × enfortumab vedotin × 90 days × Clear all

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma